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Abstract
Introduction: Multiple endocrine neoplasia type 1 (MEN 1) is a rare autosomal dominant inherited endocrine disease characterized by
pancreatic, parathyroid, and anterior pituitary tumours. Hypercalcaemia due to parathyroid tumours is usually the first manifestation of
MEN 1. Pancreatic islet tumours occur less frequently, among them gastrinomas and insulinomas are the most prevalent. Prolactinomas
are a relatively common pituitary presentation of the syndrome. The gene causing MEN 1 is localized in chromosome 11q13 and encodes
a protein named menin, which interacts with various proteins involved in transcriptional regulation, cell division, and DNA repair. Vari-
ous mutations in the menin gene have been described, but so far no strong correlation between genotype and phenotype has been found.
Case report: We report a case of a 31-year-old man, a lawyer, who was diagnosed with MEN 1 syndrome in 1999 at the age of 21 when he
was operated because of prolactinoma and hyperparathyroidism. In 2000 insulinoma was suspected and eventually multifocal lesions in
the pancreas were revealed. However, the patient did not agree to be operated on. Since then he has been followed up and has been
treated with diazoxid. We observed gradual progression of the disease, but the patient remains in relatively good condition.
Conclusions: Careful screening for MEN 1 is important in young patients with pituitary tumours. Regular follow up is crucial even after
surgical treatment. The presented patient developed gradual enlargement of insulinomas and reoccurrence of hyperparathyroidism as
well. (Pol J Endocrinol 2010; 61 (2): 212–216)
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Streszczenie
Wstęp: Zespół MEN 1 jest rzadkim schorzeniem dziedziczonym w sposób autonomiczny dominujący charakteryzujący się współwystę-
powaniem guzów trzustki, przytarczyc i przysadki. Hyperkalcemia spowodowana guzami przytarczyc jest zwykle pierwszą manifestacją
tego zespołu. Guzy trzustki występują rzadziej, a wśród nich najczęstszymi są gastrinoma i insulinoma. Guzy wydzielające prolaktynę są
stosunkowo najczęstszą przysadkową prezentacją choroby. Gen odpowiedzialny za powstanie zespołu MEN 1 jest zlokalizowany na
chromosomie 11 w pozycji 11q13 i koduje białko nazywane meniną, które wchodzi w reakcje z różnymi białkami biorącymi udział
w regulacji transkrypcji, podziału komórek i naprawie DNA. Mimo opisania różnych mutacji w genie meniny, nie znaleziono do tej pory
ścisłej korelacji pomiędzy genotypem i fenotypem.
Opis przypadku: W pracy przedstawiono przypadek 31-letniego mężczyzny, prawnika, który miał zdiagnozowany zespół MEN 1
w wieku 21 lat, kiedy był operowany z powodu guza przysadki wydzielającego prolaktynę oraz z powodu nadczynności przytarczyc.
W 2000 roku wysunięto podejrzenie insulinoma i stwierdzono wieloogniskowe zmiany w trzustce. Jednakże pacjent nie zgodził sie na
leczenie operacyjne. Od tej pory chory był leczony diazoksydem. U pacjenta obserwuje się stopniową progresję choroby, ale chory pozo-
staje w relatywnie dobrej kondycji fizycznej.
Wnioski: Badania przesiewowe w kierunku zespołu MEN 1 są szczególnie ważne u młodych chorych z guzami przysadki. Regularne
wizyty kontrolne są bardzo istotne nawet po leczeniu chirurgicznym. U prezentowanego pacjenta stopniowo powiększają się zmiany
w trzustce, również zaobserwowano nawrót nadczynności przytarczyc. (Endokrynol Pol 2010; 61 (2): 212–216)
Słowa kluczowe: zespół MEN 1, insulinoma, menina, mutacja
Introduction
Multiple endocrine neoplasia type 1 (MEN 1) is a rare
autosomal dominant inherited endocrine disorder char-
acterized by pancreatic, parathyroid, and anterior pitu-
itary tumours. Hypercalcaemia due to parathyroid tu-
mours is usually the first manifestation of MEN 1 and
occurs in 90% of patients. Pancreatic islet tumours are
less frequent and are found in 40% of cases. Gastrino-
mas with Zollinger-Ellison syndrome are the most com-
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mon. Insulinomas are the second most common, lead-
ing to hypoglycaemia, which is the cause of episodes of
fainting. Prolactinomas are a pituitary presentation of
the syndrome in 30% of cases [1]. Other organs such as
the thymus, the adrenal glands, and the skin are in-
volved less frequently [1, 2].
The tumour suppressor gene causing MEN 1 has
been localized to chromosome 11q13. It is composed of
10 exons of total length 1,830 bp and the protein product
of the MEN 1 gene is named menin. Not only have sev-
eral benign polymorphisms within the exons and introns
of the MEN 1 gene been found, but approximately
500 different germline mutations have been identified
as well [4]. The protein, which is 610-amino acids long, is
encoded by exons 2 to 10. It does not exhibit any appar-
ent sequence similarity to other known proteins [5]. The
biological role of menin remains unclear. The protein is
located mainly in cell nuclei. Involvement in cell prolif-
eration and division, and DNA repair seems possible as
menin interacts with transcription factors such as: JunD,
histone deacetylases and histone methyltransferases.
Menin also interacts directly with oestrogen receptor a
in a hormone dependent manner [3].
Heterozygous germline mutations of the MEN 1
gene have been found in 90% of families with MEN 1
syndrome. However, some germline MEN 1 mutations
are also identified in patients with clinical presentation
suggesting MEN 1 but who do not meet the exact crite-
ria of the syndrome; for instance familiar isolated hy-
perparathyroidism [3]. Various types of mutations have
been described. Frameshift mutations account for 50%
of the mutations, nonsense for 20%, and splice site for
10%, respectively. These mutations cause premature
termination of protein translation [6].
Clinical presentation of MEN 1 is very heterogeneous.
Genotype-phenotype correlations have been postulat-
ed for many years, but thus far no strict relationships have
been proven. A higher frequency of prolactinoma has
been noticed in some ethnic groups with MEN 1, but it is
unlikely that a certain type of mutation is responsible for
such pituitary tumours [7]. Almost half of MEN 1 cases
are diagnosed with pancreatoduodenal endocrine tu-
mours, which are determinants of long-term survival.
About one-third of patients develop malignant tumours
with liver metastases [2]. Surgery is the treatment of
choice for insulinomas, regardless of their size [8].
Here we report the case of a 31-year-old man with
MEN 1 and multifocal insulinomas who did not agree
to be operated and has been followed up for nine years.
Case report
A 21-year-old male was admitted to our department in
1999 after emergency surgery due to bleeding into
a pituitary tumour, which was afterwards diagnosed
as prolactinoma. As the prolactin (PRL) concentration
was elevated — 111.74 ng/mL (reference values 1.4–
–24.2) — and MRI revealed the remains of the tumour,
bromocriptine treatment was introduced, reducing PRL
to normal values. Further investigation revealed in-
creased concentrations of both calcium — 3.04 mmol/L
(reference values 2.25–2.75) — and parathormone (PTH)
— 150 pg/mL (reference values 10–70). The 99mTc MIBI
scan was contributory as the focus of high MIBI absorp-
tion was found below the left thyroid lobe (Fig. 1). Prima-
ry hyperparathyroidism as a part of MEN 1 syndrome
was diagnosed and the patient was referred to the sur-
gery department. An attempt to remove 3 and ¾ of the
fourth parathyroid glands was performed. However,
pathological examination confirmed removal of only
2 specimens of parathyroid tissues: one adenoma and
one hyperplastic gland, yet calcium and PTH concen-
trations returned to normal values.
The patient had never suffered from fainting or sei-
zures and his glucose and insulin concentrations were
normal. To exclude insulinoma, a fasting test was per-
formed. On the second day, symptomatic hypoglycae-
mia of 1.22 mmol/L occurred with an insulin level of
14.4 mIU/mL (reference fasting range 6–20 mIU/mL). CT
of the abdomen revealed a single lesion in the pancreas
(Fig. 2), but the patient did not agree to be operated.
During the next hospital stay in 2001, 111Inoctreotide
scintigraphy showed two foci of abnormal absorption
in the medial line (Fig. 3). Serotonin and 5-hydroxyin-
doleacetic acid levels were normal. Half a year later, in
MRI scans, at least two pathological lesions were visi-
ble (Fig. 4). The patient again did not give agreement
Figure 1. 99mTc MIBI scan of parathyroid glands
Rycina 1. Badanie scyntygrafii 99mTc MIBI gruczołów
przytarczycznych
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for surgical procedures. As his fasting glucose was
3.33 mmol/L, diazoxid treatment was initiated. The pa-
tient started studying law. Three years later, CT imaging
confirmed the growth of pancreatic lesions, but there
were no signs of lymph nodes or liver infiltration (Fig. 5).
At present, CT reveals gradual enlargement of multi-
focal insulinomas with no metastasis into the liver (Fig. 6).
Serum calcium concentration is 2.76 mmol/L and PTH is
144.8 pg/mL. Moreover, a 99mTc MIBI scan showed patho-
logical focal tracer concentration uptake below the right
thyroid lobe (Fig. 7). Prolactin remains within normal
values on 5 milligrams of bromocriptine daily. Insulin is
15.4 mIU/mL with no episodes of hypoglycaemia on di-
azoxid treatment. For nine years of follow up the patient
Figure 2. Computed tomography of the abdomen showing single
lesion in the pancreas
Rycina 2. Badanie tomografii jamy brzusznej pokazujące
pojedynczą zmianę w trzustce
Figure 3. 111Inoctreotide scintigraphy with 2 abnormal foci in
median line in 2001
Rycina 3. Scyntygrafia z oktreotydem (2001 rok) z 2 nieprawi-
dłowymi ogniskami w linii pośrodkowej
Figure 4. Magnetic resonance imaging of the pancreas revealing
2 pathological lesions
Rycina 4. Rezonans magnetyczny trzustki ukazujący 2 patolo-
giczne zmiany
Figure 5. Computed tomography of the abdomen showing further
growth of the lesions (year 2004)
Rycina 5. Tomografia komputerowa jamy brzusznej ukazująca
dalszy wzrost zmian (2004 rok)
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Figure 6. The latest visualization of pancreatic lesions
Rycina 6. Ostatnia wizualizacja zmian w trzustce
Discussion
We described a 31-year-old man with MEN 1 syndrome
after pituitary surgery for prolactinoma and parathy-
roid gland surgery because of hyperparathyroidism.
Coexisting multifocal insulinoma was diagnosed. How-
ever, the patient refused operative treatment of insuli-
noma and this is the reason why we present nine years
of follow up.
Neuroendocrine tumours of the pancreas account
for 2–10% of all pancreatic neoplasms [9]. Insulinomas
are of benign character in 90% of cases, but the rest are
malignant with a life expectancy of 2.5–3 years. Long-
term survival after surgical treatment is 5 years [10].
Operation and removal of the lesion is the treatment of
choice in case of functioning pancreatic tumours [11] as
these neoplasms are determinants of long-term surviv-
al. There are no clear markers of malignancy. Assess-
ment of mitotic index and Ki-67 expression has some
prognostic value. The extent of surgery has not been
fully established. Simple enucleation of the lesion is not
always possible. The younger the patient is, the more
pancreatic tissue must be preserved to prevent postop-
erative diabetes. Waldmann et al. described the case of
a 37-year-old man with MEN 1 syndrome who devel-
Figure 7. The latest 99mTc MIBI scan of parathyroid glands
Rycina 7. Ostatnia scyntygrafia 99mTc MIBI gruczołów przytarczycznych
has never suffered from episodes of fainting nor lost con-
sciousness. He still refuses surgical intervention. Inter-
estingly, the patient has already finished his law studies
and has become successful lawyer.
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oped a fast-growing neuroendocrine carcinoma. The
author suggests more frequent follow-up to detect the
early stage of tumour development [2].
As far as pharmacological treatment is concerned,
diazoxid is the treatment of choice. This agent inhibits
insulin secretion via direct action on b islet cells [10].
The most common side effects are oedema, weight gain,
and renal dysfunction. That is why sometimes diuret-
ics are added to this treatment. Somatostatin analogues,
like octreotide and lanreotide, may also be considered
in the treatment of tumours which express somatosta-
tin receptor type 2. However, in some cases they may
intensify hypoglycaemia because of the suppression of
growth hormone secretion [10, 12, 13]. In a few cases,
interferon a may be useful. The median duration of re-
sponse is 8.5 months, but all patients improve clinically
[14]. There are very scarce data of the methods and re-
sults of chemotherapy in malignant insulinomas. For
more aggressive tumours and metastatic disease, sys-
temic chemotherapy is offered. The standard chemo-
therapy for neuroendocrine pancreatic tumours is
a combination of adriamycin and streptozocine, and to
a lesser extent a combination of 5-fluorouracyl and strep-
tozocine [15]. As far as our patient is concerned, diaz-
oxid was fully adequate as there were no episodes of
hypoglycaemia and his cognitive function was good
enough to allow him to graduate from law studies.
Heterozygous germline mutations of the MEN 1
gene have been found in about 90% of familiar MEN 1
[3]. Nonetheless, more than 10% of cases do not have
any mutation in the coding region of the MEN 1 gene.
Several mutation types have been identified, of which
deletion is one of the most frequent. It often results in
early termination of the protein. Such a type of muta-
tion was found in two Italian monozygotic twins. There
were some differences in clinical presentation in com-
parison with our patient. One of the two twins suffered
from insulinoma, while the second was asymptomatic
[16]. A novel 1113delC mutation was described in
a 32-year-old male with: hypercalcaemia resulting in re-
current nephrolithiasis as a symptom of hyperparathy-
roidism, hypoglycaemia due to insulinoma, and micro-
prolactinoma. Partial pancreatectomy was the method
of treatment for insulinoma [17]. Intronic mutations also
occur in MEN 1 syndrome. Turner et al. reported intron
4 mutations in seven unrelated families. The tumours in
these families varied considerably, indicating a lack of
genotype-phenotype correlation [18]. Such a correlation
has been postulated for many years [1], but so far there
has been no strong evidence. A subtype of familiar MEN 1
characterized by an unusually high incidence of prolac-
tinoma and low frequency of enteropancreatic tumours
has been noticed in the Burin peninsula, but it seems
unlikely that particular MEN 1 mutations are responsi-
ble for this particular subtype [7]. Similarly, a group of
200 unrelated cases were investigated in the Swedish
population. There was no correlation between the sever-
ity of the disease and the mutation type and location.
A total of 69% of all mutations resulted in truncated pro-
tein. A total of 94% of all MEN 1 families had a mutation
in the coding region of the MEN 1 gene [19]. Despite
numerous investigations, a possible genotype-phenotype
correlation is very difficult to assess.
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